menu
    • menu

    Company profile for GEMoaB

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    GEMoaB GmbH is a privately-owned, clinical-stage biopharmaceutical company based in Dresden, Germany, that is focused on becoming a leading, fully integrated biopharmaceutical company. By focusing on our proprietary next generation UniCAR, RevCAR and ATAC platforms, we intend to discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients with a high unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GEMoaBGermany Flag
    Country
    Country
    Germany
    Address
    Address
    GEMoaB Monoclonals GmbH Tatzberg 47 01307 Dresden
    Telephone
    Telephone
    +49 351 4466 4500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gemoab.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GEMoaB Announces Publication of Clinical Data From Ongoing Phase I Study
    GEMoaB Announces Publication of Clinical Data From Ongoing Phase I Study

    02 Mar 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/gemoab-announces-publication-of-clinical-data-from-ongoing-phase-i-study-of-their-lead-asset-unicar-t-cd123-in-relapsedrefractory-aml-in-blood-301238246.html

    PRNEWSWIRE
    02 Mar 2021
    Share Share
    GEMoaB Announces Presentation of Translational Data From Ongoing Phase I Study
    GEMoaB Announces Presentation of Translational Data From Ongoing Phase I Study

    10 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/gemoab-announces-presentation-of-translational-data-from-ongoing-phase-i-clinical-study-of-their-lead-asset-unicar-t-cd123-in-relapsedrefractory-aml-at-the-upcoming-2021-aacr-annual-meeting-301225762.html

    PRNEWSWIRE
    10 Feb 2021
    Share Share
    GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study
    GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study

    03 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/gemoab-announces-unicar-t-cd123-data-from-its-ongoing-phase-i-study-in-patients-with-relapsedrefractory-aml-rraml-to-be-presented-at-virtual-3rd-eha-ebmt-european-car-t-cell-meeting-301221278.html

    PRNEWSWIRE
    03 Feb 2021
    Share Share
    GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients
    GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients

    03 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/gemoab-announces-unicar-t-cd123-data-from-its-ongoing-phase-i-study-in-patients-with-relapsedrefractory-aml-rraml-to-be-presented-at-virtual-3rd-eha-ebmt-european-car-t-cell-meeting-301221278.html

    PRNEWSWIRE
    03 Feb 2021
    Share Share
    GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123
    GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123

    07 Jan 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/gemoab-announces-clinical-data-presentations-on-their-lead-asset-unicar-t-cd123-in-relapsedrefractory-aml-at-the-upcoming-eha-ebmt-3rd-european-car-t-cell-meeting-301201927.html

    PRNEWSWIRE
    07 Jan 2021
    Share Share
    GEMoaB and Intellia Therapeutics Enter into Research Collab and Agreement
    GEMoaB and Intellia Therapeutics Enter into Research Collab and Agreement

    20 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/gemoab-and-intellia-therapeutics-enter-into-research-collaboration-and-licensing-agreement-on-next-generation-cellular-immunotherapy-based-on-proprietary-revcar-and-crisprcas9-genome-editing-platforms-301096049.html

    PRNEWSWIRE
    20 Jul 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search